What's happened
The Royal College of Nursing and the Royal College of Pharmacy have dropped Teva UK from sponsorships and exhibitions, citing ongoing due diligence and concerns over Teva’s activities. Campaign groups have urged further action across other royal colleges and NHS purchasing decisions. Teva has faced multiple fines for price-fixing and sanctions in recent years.
What's behind the headline?
Writing quality analysis (markdown)
- This update is a shift in ethical partnerships affecting health professional bodies. The piece should foreground the patient and public-interest implications while clearly identifying which organisations have severed ties and why.
- The story sits at the intersection of healthcare accountability and corporate ethics; readers will want concrete actions and timelines.
- The rising chorus from pro-Palestine campaigners adds pressure on other royal colleges to reassess sponsors, potentially reshaping NHS procurement channels.
Key angles to watch: which organisations follow suit, what thresholds prompt withdrawal, and how this influences patient access to medicines priced by Teva.
How we got here
Teva UK entered sponsorship deals with UK royal colleges, including a £15,000 package for four conference events. Following a charity status in April and due diligence reviews, these bodies are reevaluating partnerships with Teva amid scrutiny of the Israeli company’s activities and broader-linked controversy surrounding Israel’s actions in Gaza. Past corporate misconduct by Teva includes fines in Europe and the US.
Our analysis
The Guardian reports that the RCN and Royal College of Pharmacy have ended Teva UK sponsorships following due diligence reviews; The New Arab notes continued public scrutiny and broader industry actions. The Guardian’s earlier piece confirms the RCN’s decision and outlines Teva’s fines for price-fixing and sanctions. Additional context comes from UKHPRC’s statements and Nurses for Palestine campaigns.
Go deeper
- Will more royal colleges sever Teva’s sponsorships?
- What specific activities prompted the due diligence reviews?
- How will NHS purchasing be affected if more sponsors drop Teva?
More on these topics
-
Mexico - Country in North America
Mexico, officially the United Mexican States, is a country in the southern portion of North America. It is bordered to the north by the United States; to the south and west by the Pacific Ocean; to the southeast by Guatemala, Belize, and the Caribbean Sea
-
Ukraine - Country in Europe
Ukraine is a country in Eastern Europe. It is the second-largest European country after Russia, which borders it to the east and northeast.
-
Russia - Country
Russia, or the Russian Federation, is a transcontinental country located in Eastern Europe and Northern Asia. Covering an area of 17,125,200 square kilometres, it is the largest country in the world by area, spanning more than one-eighth of the Earth's in
-
Royal College of Nursing - Trade union
The Royal College of Nursing is a membership organisation and trade union with 450,000 members in the United Kingdom. It was founded in 1916, receiving its royal charter in 1928. Her Majesty Queen Elizabeth II is the patron.
-
United Kingdom - Country in Europe
The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom or Britain, is a sovereign country located off the northwestern coast of the European mainland.
-
European Commission - Governing body of protected sites
The European Commission is the executive branch of the European Union, responsible for proposing legislation, implementing decisions, upholding the EU treaties and managing the day-to-day business of the EU.
-
Teva Pharmaceutical Industries Ltd. - Israeli pharmaceutical company
Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo (deutetrabenazine) which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy (fremanezumab), used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation...
-
Royal Pharmaceutical Society - Organization
The Royal Pharmaceutical Society is the body responsible for the leadership and support of the pharmacy profession within England, Scotland and Wales.
-
Israel - Country in the Middle East
Israel, formally known as the State of Israel, is a country in Western Asia, located on the southeastern shore of the Mediterranean Sea and the northern shore of the Red Sea.